Results 151 to 160 of about 2,540 (169)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials

Cardiovascular Research, 2020
Arjen J Cupido, , Kastelein John J P
exaly  

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Clinical Research in Cardiology, 2023
U Schatz, Eitel I, Koenig W
exaly  

Inclisiran jetzt verfügbar

MMW - Fortschritte der Medizin, 2021
openaire   +1 more source

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

New England Journal of Medicine, 2020
Kausik K Ray, R Scott Wright, Wolfgang Koenig   +2 more
exaly  

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

Expert Opinion on Drug Safety, 2022
Yajnavalka Banerjee, Anca Pantea Stoian, Arrigo F G Cicero   +2 more
exaly  

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Journal of Clinical Lipidology, 2022
Robert Stoekenbroek, Yan-Ling He, Patrick F Smith   +2 more
exaly  

<p>Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential</p>

Therapeutics and Clinical Risk Management, 2020
Constantine E Kosmas, Alba Munoz Estrella   +1 more
exaly  

Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic

Journal of Clinical Lipidology, 2023
Pam R Taub, Michael J Wilkinson, Tommy Chiou   +2 more
exaly  

Estimation of the major cardiovascular events prevention with Inclisiran

Atherosclerosis, 2020
Alberto Cordero, CARLOS G Santos-Gallego, Lorenzo Facila   +2 more
exaly  

Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program

Future Cardiology, 2018
Robert M Stoekenbroek, John Jp Kastelein
exaly